Publication: Regulatory effect of Phikud Navakot extract on HMG-CoA reductase and LDL-R: Potential and alternate agents for lowering blood cholesterol
Issued Date
2018-09-24
Resource Type
ISSN
14726882
Other identifier(s)
2-s2.0-85053845841
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
BMC Complementary and Alternative Medicine. Vol.18, No.1 (2018)
Suggested Citation
Napatara Tirawanchai, Sudarat Supapornhemin, Anchaleekorn Somkasetrin, Bhoom Suktitipat, Sumate Ampawong Regulatory effect of Phikud Navakot extract on HMG-CoA reductase and LDL-R: Potential and alternate agents for lowering blood cholesterol. BMC Complementary and Alternative Medicine. Vol.18, No.1 (2018). doi:10.1186/s12906-018-2327-1 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46315
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Regulatory effect of Phikud Navakot extract on HMG-CoA reductase and LDL-R: Potential and alternate agents for lowering blood cholesterol
Other Contributor(s)
Abstract
© 2018 The Author(s). Background: For decades, various cardiovascular symptoms have been relieved by the use of Ya-Hom Navakot, which is a formulation comprising 54 herbal medicines. The Thailand Ministry of Public Health listed Ya-Hom Navakot's nine active principle and nomenclative herbal ingredients and termed them 'Phikud Navakot' (PN). Several reports have confirmed that PN has cardiovascular benefits similar to Ya-Hom Navakot. However, whether PN facilitates lipid-lowering activity remains unclear. Methods: The present study investigated an in vitro model for examining the gene expression levels of 3-hydroxyl-3-methylglutaryl-CoA reductase (HMGCR) and low-density lipoprotein receptor (LDL-R) in HepG2 cells using qRT-PCR. The ethanol and water extractions of Ya-Hom Navakot, PN and Ya-Hom Navakot without PN were compared. Results: One mg/ml of both NYEF and NYWF were found to significantly lower cholesterol by either the up-regulation of LDL-R or down-regulation of HMGCR compared with negative controls and 1 mg/ml simvastatin (p < 0.05). PNEF also up-regulated LDL-R gene expression, even more than NYEF (p < 0.05). In addition, the ethanol and water extracts of PN significantly down-regulated HMGCR gene expression compared with those of Ya-Hom Navakot without PN (p < 0.05). Conclusion: The use of Ya-Hom Navakot or PN may provide an alternative treatment to lower cholesterol through HMGCR gene inhibition and LDL-R gene enhancement.